It has been a rough few months for pharmaceutical and healthcare companies. The overnight price hike of Daraprim, a drug to treat AIDs, cancer, and malaria, by a biotech company led by Martin Shkreli in mid-September garnered public outrage and political backlash. Presidential candidate Hillary Clinton later described the move as 'outrategous', and the Democratic members of the House Oversight Committee have subsequently requested a hearing regarding the outsized price hikes.